Surfing the MASH Tsunami

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen Harrison reviews the top-line results of Altimmune’s 12 week Phase 1B study of pemvidutide , a GLP-1/glucagon dual receptor agonist. Stephen describes the effects of pemvidutide on the liver’s fat cre...

Send us Fan Mail A recent string of press releases has presaged some of the most exciting, promising data of the last decade in NASH drug development. In this episode,  Stephen Harrison reviews recent press releases from Altimmune, Akero, Poxel, Axcella and Intercept, while Jörn Schattenberg, Louise Campbell, special guest Mazen Noureddin and Roger Green share questions and impressions.  Last mont...

Send us Fan Mail In this episode From the Vault, Surfers Roger Green and Louise Campbell are joined by Professor Ian Rowe to discuss the implications of the FDA approval of the ELF test. For Ian, the ELF approval was the most important story of summer 2021. The test promises a brighter future for non-invasive tests and, eventually, decreased reliance on biopsy. Ian points out that transitioning fr...

Send us Fan Mail After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. In this final conversation, the group discusses the importance of combination NIT biomarkers in developing a viable system for treating patients. The key is that NITs provide a viable strategy...

Send us Fan Mail After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation speculates where potential bottlenecks in getting drugs to patients might emerge. Louise points to payers as a significant barrier en route to product adoption. Roger suggests...

Send us Fan Mail After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation focuses on exciting data they anticipate for multiple different drugs. They also discuss the implications positive drug trials and anticipated approvals will have for NAFLD tr...

Send us Fan Mail After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation explores the role of multiple biomarker tests in the diagnostic process and how these might vary in the panelists’ home countries. To begin, Louise notes that in the UK, many...

Send us Fan Mail After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation focuses on the need for different specialties to align in treating the complete range of non-communicable metabolic diseases. Jörn starts the conversation with a personal high...

Send us Fan Mail The last month has witnessed several major Fatty Liver conferences and others that touch on NAFLD in the context of metabolic disease. One common theme has been the need for different specialties to align in treating the complete range of non-communicable metabolic diseases. In this episode, Roger Green, Jörn Schattenberg and Louise Campbell propose factors that have the potential...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In Season 3, Episode 46, program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green on-site from Dublin to review their reactions immediately after the conference ended. The panelists note the impact of weight change and lifestyle modification in cl...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their reactions immediately after the conference ended. This final conversation begins with Roger calling attention to a debate around NITs that took p...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green on-site from Dublin to review their reactions immediately after the conference ended. In this conversation, the panelists examine the impact of weight change and lifestyle modification in cl...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In this conversation, the panelists explore issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality. This conversation addr...

Send us Fan Mail The 2022 NAFLD Summit uniquely presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their reactions immediately after the conference ended.  At the outset of this episode, the group discusses the benefits of participating in a...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer Roger Green, on-site from Dublin to review their reactions immediately after the conference ended.  In this episode, the panelists discuss presentations and sessions they found particularly compe...

Send us Fan Mail The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In this episode, program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the conference ended. Roger starts by asking each to choose and elaborate on one pr...

Send us Fan Mail In Season 3, Episode 19, the content focus looks at what the retrospective analysis from the NAIL-NIT consortium can achieve in terms of moving the shift beyond the biopsy in NASH diagnostics forward. This conversation starts with Stephen discussing how challenging it was to develop initial FDA test criteria for evaluating NASH drugs. Many years later, he notes, we have learned ho...

Send us Fan Mail In this episode, the group covers the Day Two program and offers final thoughts on the Paris NASH 2022 review. The conversation starts with Louise introducing the discussion around estrogen replacement therapy and fatty liver in post-menopausal women. She notes this an area of opportunity for improving women’s health. Next, Arun Sanyal’s science lecture on NITs is discussed. The l...

Send us Fan Mail This episode addresses the other talks in Session 5 focusing on clinical trial innovation, after Frank Anania’s opener. Roy Sabo presented a cogent, comprehensible discussion of the value of adaptive trial strategies. Roger relates the presentation to a conversation on the NASH Tsunami last month with Stephen Harrison. Stephen introduced an example of adjusting FibroScan threshold...

Send us Fan Mail The episode starts with Louise sounding an alarm about the rate of growth for cirrhosis and bridging or advanced cirrhosis. She is concerned that as more data is collected, an increasing number of lives fail to be served with the passage of time. She then mentions a talk by Oxana Drapkina from Session 1 about how the Russian system operates. On the surface, this sounds to be more...

Send us Fan Mail The episode begins with the panelists - Jörn, Louise, Jeff McIntyre of GLI and Roger - discussing one thing each found particularly striking at the recent Paris NASH  meeting. Most comments centered around three themes: 1. A general appreciation of the quality and diversity of talks at Paris NASH. 2. Disappointment with the regulatory response from Frank Anania of FDA on the quest...

Send us Fan Mail The importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meeting . Last week, Surfers Roger Green, Louise Campbell and Jörn Schattenberg were in attendance alongside patient advocate and episode guest, Jeff McIntyre. The conversation starts with Roger asking the group about one thing each found particularl...

Send us Fan Mail This week, Surfing the NASH Tsunami discusses a preview of the 8th Paris NASH Meeting taking place on September 8th & 9th, 2022. Paris NASH is a meeting for basic science and interdisciplinary thinking. Key opinion leaders from both sides of the Atlantic come together to present pivotal learnings and host exciting discussions on fatty liver diseases. In this conversation from...

Send us Fan Mail Roger starts by asking Jeff to describe his role in the NAFLD Summit and to discuss any other presentations of interest outside of his own. Jeff shares that he will be talking about evolving models of care and future implications. His interest in the session stems not just from his presenting, but from the session title, "Epidemiology, Disease Modifiers and Models of Care,&qu...

Send us Fan Mail Roger Green starts this interview with Jeff Lazarus by asking what Jeff has been focusing on since the Barcelona conference in May. Jeff describes his extensive daily efforts to develop and garner support for a global consensus strategy on COVID-19, similar to his work on a global consensus statement on Fatty Liver disease. (This was the topic of Season 2, Episode 59 .) Like the F...